BioHarvest Sciences Inc. BHST
1.51 USD -0.13 (-7.67%)
Regular-session close
1.43 -0.07 -4.98%
After hours · Nov 13, 4:00 PM ET
1.45 Day range 1.64
1.45 52-week range 7.30
- YTD
- -71.00%
- 1 year
- -79.38%
News
seekingalpha.com BioHarvest Sciences Inc. (BHST) Q3 2026 Earnings Call Transcript BioHarvest Sciences Inc. (BHST) Q3 2026 Earnings Call Transcriptbenzinga.com Conference call: BioHarvest Sciences Lowers FY2026 Sales Guidance from $37.000M-$40.000M to $32.000M-$33.500M vs $37.461M Est BioHarvest Sciences (NASDAQ:BHST) lowers FY2026 sales outlook from $37.000 million-$40.000 million to $32.000 million-$33.500 million vs $37.461 million estimate.
benzinga.com BioHarvest Sciences Q3 2026 Earnings Call Transcript BioHarvest Sciences (NASDAQ:BHST) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
zacks.com BioHarvest Sciences Inc. (BHST) Reports Q3 Loss, Misses Revenue Estimates BioHarvest Sciences Inc. (BHST) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.14 per share a year ago.benzinga.com BioHarvest Sciences Inc. - Common Stock Q3 EPS $(0.15) Misses $(0.14) Estimate, Sales $7.867M Miss $9.371M Estimate BioHarvest Sciences Inc. - Common Stock (NASDAQ:BHST) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.14) by 7.14 percent. This is a 7.14 percent…
newsfilecorp.com BioHarvest Reports Third Quarter 2026 Financial Results and Provides Business Update Prioritizes cash preservation and controlled VINIA growth while concentrating CDMO resources on advanced programs with near-term manufacturing potential Vancouver, British Columbia and Rehovot,…
defenseworld.net BioHarvest Sciences (NASDAQ:BHST) and Haleon (NYSE:HLN) Head to Head Contrast BioHarvest Sciences (NASDAQ: BHST - Get Free Report) and Haleon (NYSE: HLN - Get Free Report) are both consumer staples companies, but which is the better investment? We will compare the two…
defenseworld.net Solesence (NASDAQ:SLSN) versus BioHarvest Sciences (NASDAQ:BHST) Financial Review Solesence (NASDAQ: SLSN - Get Free Report) and BioHarvest Sciences (NASDAQ: BHST - Get Free Report) are both small-cap consumer staples companies, but which is the superior stock? We will contrast…
defenseworld.net BioHarvest Sciences (NASDAQ:BHST) & Interparfums (NASDAQ:IPAR) Head to Head Analysis BioHarvest Sciences (NASDAQ: BHST - Get Free Report) and Interparfums (NASDAQ: IPAR - Get Free Report) are both consumer staples companies, but which is the better business? We will contrast the two…
newsfilecorp.com BioHarvest Sciences to Report Third Quarter 2026 Financial Results on November 12, 2026 Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - October 29, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (TASE: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a leader in…
proactiveinvestors.com BioHarvest takes second plant-cell asset to commercial readiness BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) said on Tuesday that Olive Cell, an olive-derived plant-cell ingredient, is ready for commercial licensing, the second product from its Botanical…benzinga.com BioHarvest Sciences' Proprietary Olive Cell Composition Attains Commercial Readiness, Now Available For Licensing And Commercialization Botanical Synthesis™-developed asset has now completed development, commercial-scale manufacturing and the applicable self-affirmed GRAS process and is ready for production at BioHarvest's GMP…
newsfilecorp.com BioHarvest Advances Proprietary Olive Cell Asset to Commercial Readiness, Opening New CDMO Licensing Opportunity Botanical Synthesis™-developed asset has now completed development, commercial-scale manufacturing and the applicable self-affirmed GRAS process and is ready for production at BioHarvest's GMP…
proactiveinvestors.com BioHarvest says its platform can produce target sweetener in Tate & Lyle program BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) said on Thursday its Botanical Synthesis platform can produce the next-generation sweetener targeted in its joint development program with Tate & Lyle.…
newsfilecorp.com Tate & Lyle and Bioharvest Reach Key Milestone in Next-Generation Sweetener Development Programme Progress demonstrates that BioHarvest's Botanical Synthesis(TM) platform is capable of producing the targeted next-generation sweetening solution Vancouver, British Columbia and Rehovot,…
proactiveinvestors.com BioHarvest Sciences launches buyback of up to 5% of shares BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) said Tuesday its board has authorized a share repurchase program covering up to 5% of its outstanding common shares. The company, which develops and…benzinga.com BioHarvest Sciences Board Authorizes Normal Course Issuer Bid To Repurchase Up To 5% Of Outstanding Common Shares BioHarvest Sciences Inc. (NASDAQ:BHST) (TASE: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a Botanical Synthesis company developing and manufacturing proprietary plant-based compositions for
newsfilecorp.com BioHarvest Sciences Announces Share Repurchase Program Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - September 29, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (TASE: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a Botanical…
newsfilecorp.com BioHarvest Advances Botanical Synthesis Leadership as VINIA Daily Chews Unlock More Value from Its First Consumer Product Single-dose VINIA Daily Chews broaden demographics and usage occasions while demonstrating the commercial versatility of Botanical Synthesis Format expansion shows how BioHarvest can help CDMO…
newsfilecorp.com BioHarvest Sciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - September 14, 2026) - BioHarvest Sciences Inc (NASDAQ: BHST) (TASE: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology…
proactiveinvestors.com Fiinu shares jump over 6% as Conister Bank platform enters production Fiinu (AIM: BANK), the UK fintech group, rose over 6% to 4p on Friday after its Plugin Overdraft platform moved into production ahead of a planned year-end...
proactiveinvestors.com BioHarvest Sciences plans Tel Aviv Stock Exchange dual listing BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) plans to pursue a dual listing of its ordinary shares on the Tel Aviv Stock Exchange (TASE), with trading expected to begin on September 8, 2026. The…
newsfilecorp.com BioHarvest Sciences Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE) Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - September 3, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable…benzinga.com Maxim Group Maintains Buy on BioHarvest Sciences, Lowers Price Target to $5 Maxim Group analyst Anthony Vendetti maintains BioHarvest Sciences (NASDAQ:BHST) with a Buy and lowers the price target from $12 to $5.
benzinga.com Roth Capital Maintains Buy on BioHarvest Sciences, Lowers Price Target to $8 Roth Capital analyst Sean McGowan maintains BioHarvest Sciences (NASDAQ:BHST) with a Buy and lowers the price target from $10 to $8.
benzinga.com Conference Call: BioHarvest Sciences Lowers FY2026 Sales Guidance from $42.000M-$48.000M to $37.000M-$40.000M vs $42.914M Est BioHarvest Sciences (NASDAQ:BHST) lowers FY2026 sales outlook from $42.000 million-$48.000 million to $37.000 million-$40.000 million vs $42.914 million estimate.
seekingalpha.com BioHarvest Sciences Inc. (BHST) Q2 2026 Earnings Call Transcript BioHarvest Sciences Inc. (BHST) Q2 2026 Earnings Call Transcript
marketbeat.com BioHarvest Sciences Q2 Earnings Call Highlights BioHarvest Sciences NASDAQ: BHST reported second-quarter 2026 revenue of $8.8 million, up 3.8% from $8.5 million a year earlier, while highlighting its first manufacturing and supply agreement within…benzinga.com BioHarvest Sciences Revises FY26 CDMO Revenue Guidance to $4M-$5M from $4M-$6M; VINIA D2C Revenue Guidance to $33M-$35M from $38M-$42M BioHarvest Sciences (NASDAQ:BHST) stated that full-year 2026 revenue guidance for its CDMO business has been narrowed to $4 million-$5 million, from $4 million-$6 million previously, while revenue…
benzinga.com BioHarvest Sciences Enters Agreement For A Rare, Endangered Fragrance Plant Cell Culture With A UAE-Based Customer; Sees $20M-$30M In 2027-28 Sales This particular scent is widely regarded as one of the most valuable fragrance raw materials in the world, with premium grades commanding prices exceeding tens of thousands of U.S. dollars per…
benzinga.com BioHarvest Sciences Receives $1.4M Grant Approval From Israel Innovation Authority BioHarvest Sciences Inc (NASDAQ:BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that the Israel Innovation Authority…
benzinga.com BioHarvest Sciences Expands Its Joint Sweetener Development Program With Tate & Lyle To Include Multiple Plant-Based Sweetener Molecules The expanded collaboration builds on the initial agreement signed in 2024 and reflects strong technical progress to date, as well as Tate & Lyle's ambition to equip food and beverage manufacturers…
benzinga.com BioHarvest Sciences Affirms FY2026 Sales Guidance of $42.000M-$48.000M vs $44.721M Est BioHarvest Sciences (NASDAQ:BHST) affirms FY2026 sales outlook from $42.000 million-$48.000 million to $42.000 million-$48.000 million vs $44.721 million estimate.
benzinga.com BioHarvest Sciences Q1 EPS $(0.11) Beats $(0.12) Estimate, Sales $8.500M Miss $8.796M Estimate BioHarvest Sciences Inc. - Common Stock (NASDAQ:BHST) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.12) by 8.33 percent. This is a 15.38 percent…
benzinga.com Earnings Scheduled For May 14, 2026 benzinga.com BioHarvest Sciences' CDMO Division Completes Stage 1 Under Multi-Stage Development Agreement, Establishing Stable Saffron Cell Bank For Potential Nutraceutical And Culinary Applications - CDMO program advances to Stage 2 of development agreement valued at $1.125 million-Advancement of sustainable solution for the production of saffron, one of the world's most valuable and…
benzinga.com BioHarvest Sciences' CDMO Division Signs $1.2M Stage 2 Contract As Part Of Multi-Stage Development Program For Rare Scent-Producing Plant Used In Global Fragrance Industry BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that…
benzinga.com BioHarvest Sciences Sees FY2026 Sales $42.000M-$48.000M vs $48.432M Est BioHarvest Sciences (NASDAQ:BHST) sees FY2026 sales of $42.000 million-$48.000 million vs $48.432 million analyst estimate.
benzinga.com BioHarvest Sciences Inc. - Common Stock Q4 EPS $(0.10), Inline, Sales $9.100M Miss $9.279M Estimate BioHarvest Sciences Inc. - Common Stock (NASDAQ:BHST) reported quarterly losses of $(0.10) per share which met the analyst consensus estimate. This is a 41.18 percent increase over losses of $(0.17)…
benzinga.com BioHarvest Sciences Announces First Successful Stage 1 Stable Cell Culture Of Scent-Producing Plant With Stage 1 now completed, BioHarvest is ready to advance to Stage 2, where cells stored in a proprietary cell bank will be propagated in liquid medium to generate significant biomass. Once stage 2…
benzinga.com Earnings Scheduled For March 31, 2026
benzinga.com This Tempus AI Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday benzinga.com Roth Capital Initiates Coverage On BioHarvest Sciences with Buy Rating, Announces Price Target of $10 Roth Capital analyst Sean McGowan initiates coverage on BioHarvest Sciences (NASDAQ:BHST) with a Buy rating and announces Price Target of $10.
benzinga.com Earnings Scheduled For November 13, 2025 benzinga.com Earnings Scheduled For August 11, 2025
benzinga.com Earnings Scheduled For May 15, 2025
benzinga.com Earnings Scheduled For March 31, 2025
